Comparison between upfront transplantation and different pre-transplant cytoreductive treatment approaches in patients with high-risk MDS and secondary AML

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia derived from MDS (sAML) [1,2]. However, there is controversy among experts if and how patients with MDS should receive cytoreductive “debulking” chemotherapy before transplant. MDS patients without elevated bone marrow blast counts usually proceed to transplant without cytoreduction, whereas patients with MDS and excess blasts and those with sAML often receive cytoreductive treatment in order to achieve remission before trans plant [1,3].

Source: Biology of Blood and Marrow Transplantation - March 13, 2019 Category: Hematology Authors: Thomas Schroeder, Nadija Wegener, Michael Lauseker, Christina Rautenberg, Kathrin Nachtkamp, Esther Schuler, Mustafa Kondakci, Rainer Haas, Ulrich Germing, Guido Kobbe Source Type: research